Monte Rosa Therapeutics Inc
monterosatx.comMonte Rosa Therapeutics (NASDAQ: GLUE) is a clinical-stage biopharmaceutical company that discovers and develops molecular glue degrader drug candidates. Revenue comes from licensing and collaboration agreements with pharmaceutical partners, not from commercial product sales. As of the 10-K filed March 17, 2026, revenues have consisted primarily of consideration from the Roche Agreement, the 2024 Novartis License Agreement, and the 2025 Novartis License Agreement. The company has no approved products and operates as a pre-commercial drug discovery and development organization. Its QuEEN drug discovery engine, which incorporates AI, underpins its molecular glue degrader platform. Operations span two locations: a primary site and an office and laboratory space of 44,685 square feet in Basel-City, Switzerland, with the lease extended through June 2027. CEO Markus Warmuth, M.D. serves as both President and Principal Executive Officer as of March 17, 2026.
Products & Services
Molecular glue degrader drug candidates; QuEEN drug discovery engine incorporating AI for drug discovery.
Revenue Model
Licensing and collaboration agreements, specifically the Roche Agreement, the 2024 Novartis License Agreement, and the 2025 Novartis License Agreement, recognized under ASC 606 as performance obligations are satisfied. No commercial product revenue as of the filing date.
Customers & Markets
Pharmaceutical partners Roche and Novartis, as named in the 10-K filed March 17, 2026. End market is targeted protein degradation therapeutics.
Geographic Exposure
United States (primary operations) and Basel-City, Switzerland (44,685 square feet office and laboratory space, lease through June 2027).
Financial Snapshot
Loading...
